+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Polycystic Ovarian Syndrome Treatment Market by Treatment Type, Drug Class, Route of Administration, Distribution Channel, End User, Patient Type - Global Forecast to 2030- Product Image
Polycystic Ovarian Syndrome Treatment Market by Treatment Type, Drug Class, Route of Administration, Distribution Channel, End User, Patient Type - Global Forecast to 2030- Product Image
Sale

Polycystic Ovarian Syndrome Treatment Market by Treatment Type, Drug Class, Route of Administration, Distribution Channel, End User, Patient Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5666528
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Polycystic Ovarian Syndrome Treatment Market is experiencing steady growth, driven by innovation in diagnostics, digital health integration, and evolving clinical preferences. Senior decision-makers in healthcare and pharma will find actionable insights on market shifts, competitive tactics, and strategic opportunities tailored to the complex needs of PCOS therapy.

Market Snapshot: Polycystic Ovarian Syndrome Treatment Market

The Polycystic Ovarian Syndrome (PCOS) Treatment Market grew from USD 3.45 billion in 2024 to USD 3.68 billion in 2025. It is expected to continue growing at a CAGR of 6.72%, reaching USD 5.09 billion by 2030. This trend reflects rising global awareness, broadening research initiatives, and the adoption of tailored, patient-centric solutions. The market’s expansion is supported by innovations that span digital therapeutics, advanced drug formulations, and integrated care pathways, emphasizing the need for robust segmentation and region-specific strategies.

Scope & Segmentation

This report delivers a comprehensive analysis across core segments, end-user profiles, and regional markets:

  • Treatment Types: Lifestyle management, pharmacological interventions, surgical procedures including bariatric surgery and ovarian drilling
  • Drug Classes: Anti-androgens (such as flutamide, spironolactone), insulin-sensitizing agents (metformin, thiazolidinediones), oral contraceptives (combined and progestin-only)
  • Routes of Administration: Oral therapies, injectable options (intramuscular and subcutaneous), topical applications
  • Distribution Channels: Hospital pharmacies, online pharmacies, retail pharmacies
  • End Users: Clinics, homecare settings, hospitals, specialty centers
  • Patient Types: Adolescents (under 18, 16 to 18 years), adults (18-35 and 36-45)
  • Regions: Americas (including United States, Canada, Brazil), Europe, Middle East & Africa (UK, Germany, France, UAE, South Africa), Asia-Pacific (China, India, Japan, Australia, and others)
  • Featured Companies: Bayer AG, Teva Pharmaceutical Industries Ltd., Viatris Inc., Ferring International Center S.A., Dr. Reddy’s Laboratories Limited, GlaxoSmithKline plc, Merck KGaA, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Limited

Key Takeaways

  • Integrated care models—combining lifestyle management, pharmacological therapy, and selective surgical options—are increasingly preferred for addressing the full spectrum of PCOS symptoms.
  • Technology is transforming the patient journey, with digital health platforms and advanced diagnostics enabling earlier, more precise phenotyping and personalized treatment adjustments.
  • Therapy adherence is being improved via sustained-release therapies, microdose injectables, and connected devices, reducing the burden of chronic disease management.
  • Segmentation by patient age and risk profile helps optimize dosage, education, and monitoring strategies—supporting more targeted marketing and resource allocation.
  • Distinctions in regional reimbursement frameworks, healthcare infrastructure, and supply chain logistics drive the need for localized approaches to market penetration and scaling.

Tariff Impact for 2025

Anticipated tariff increases on pharmaceutical imports in the United States are expected to reshape cost structures and challenge supply reliability for key PCOS therapies. Raw materials used in essential medications may see increased import duties, prompting manufacturers to diversify sourcing, invest in local partnerships, and advocate for targeted regulatory exemptions. Industry players are advised to engage in scenario planning and procurement strategy adjustments to maintain continual patient access and profitability.

Methodology & Data Sources

Research is grounded in a mixed-methods approach, combining primary interviews with endocrinologists, gynecologists, payers, and industry executives, alongside expert surveys for opinion-based insights. Secondary research incorporates scientific literature, regulatory data, annual reports, and clinical trial registries. Data triangulation, rigorous error checks, and peer review underpin analytical reliability and ensure all findings align with industry best practices.

Why This Report Matters

  • Enables leadership teams to align product pipelines and distribution with the latest trends in PCOS therapy and patient segmentation.
  • Equips executives with strategic intelligence for navigating supply chain pressures and regulatory shifts, including tariffs.
  • Empowers stakeholders to develop precision marketing, optimize operational models, and improve long-term patient outcomes through actionable data.

Conclusion

This analysis delivers senior decision-makers the clarity needed to refine strategic direction and harness emerging opportunities in the PCOS treatment market. Organizations prioritizing innovation, partnership, and evidence-driven differentiation will be positioned for long-term success in this evolving landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Polycystic Ovarian Syndrome Treatment Market, by Treatment Type
8.1. Introduction
8.2. Lifestyle Management
8.3. Pharmacological Treatment
8.4. Surgical Treatment
8.4.1. Bariatric Surgery
8.4.2. Ovarian Drilling
9. Polycystic Ovarian Syndrome Treatment Market, by Drug Class
9.1. Introduction
9.2. Anti-Androgens
9.2.1. Flutamide
9.2.2. Spironolactone
9.3. Insulin-Sensitizing Agents
9.3.1. Metformin
9.3.2. Thiazolidinediones
9.4. Oral Contraceptives
9.4.1. Combined Oral Contraceptives
9.4.2. Progestin-Only Pills
10. Polycystic Ovarian Syndrome Treatment Market, by Route of Administration
10.1. Introduction
10.2. Injectable
10.2.1. Intramuscular Injection
10.2.2. Subcutaneous Injection
10.3. Oral
10.4. Topical
11. Polycystic Ovarian Syndrome Treatment Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Polycystic Ovarian Syndrome Treatment Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Homecare Settings
12.4. Hospitals
12.5. Specialty Centers
13. Polycystic Ovarian Syndrome Treatment Market, by Patient Type
13.1. Introduction
13.2. Adolescents
13.2.1. 16 to 18 Years
13.2.2. Under 18 Years
13.3. Adults 18-35
13.4. Adults 36-45
14. Americas Polycystic Ovarian Syndrome Treatment Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Polycystic Ovarian Syndrome Treatment Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Bayer AG
17.3.2. Teva Pharmaceutical Industries Ltd.
17.3.3. Viatris Inc.
17.3.4. Ferring International Center S.A.
17.3.5. Dr. Reddy’s Laboratories Limited
17.3.6. GlaxoSmithKline plc
17.3.7. Merck KGaA
17.3.8. Novartis AG
17.3.9. Pfizer Inc.
17.3.10. Sun Pharmaceutical Industries Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY LIFESTYLE MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY BARIATRIC SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY OVARIAN DRILLING, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY FLUTAMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SPIRONOLACTONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY METFORMIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY THIAZOLIDINEDIONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY 16 TO 18 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY UNDER 18 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADULTS 18-35, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADULTS 36-45, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 75. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 76. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 77. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2030 (USD MILLION)
TABLE 79. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2030 (USD MILLION)
TABLE 80. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 81. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 83. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 86. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 87. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 88. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 89. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 90. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2030 (USD MILLION)
TABLE 91. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2030 (USD MILLION)
TABLE 92. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 93. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 95. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 98. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 136. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 137. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 148. GERMANY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 149. GERMANY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 150. GERMANY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 151. GERMANY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2030 (USD MILLION)
TABLE 152. GERMANY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2030 (USD MILLION)
TABLE 153. GERMANY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 154. GERMANY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. GERMANY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 156. GERMANY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. GERMANY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. GERMANY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 159. GERMANY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 160. FRANCE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 161. FRANCE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 162. FRANCE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 163. FRANCE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2030 (USD MILLION)
TABLE 164. FRANCE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2030 (USD MILLION)
TABLE 165. FRANCE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 166. FRANCE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. FRANCE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 168. FRANCE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. FRANCE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. FRANCE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 171. FRANCE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 172. RUSSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 173. RUSSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 174. RUSSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 175. RUSSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2030 (USD MILLION)
TABLE 176. RUSSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2030 (USD MILLION)
TABLE 177. RUSSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 178. RUSSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. RUSSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 180. RUSSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. RUSSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. RUSSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 183. RUSSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 184. ITALY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 185. ITALY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 186. ITALY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 187. ITALY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2030 (USD MILLION)
TABLE 188. ITALY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2030 (USD MILLION)
TABLE 189. ITALY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 190. ITALY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 191. ITALY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 192. ITALY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. ITALY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. ITALY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 195. ITALY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 196. SPAIN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 197. SPAIN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 198. SPAIN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 199. SPAIN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2030 (USD MILLION)
TABLE 200. SPAIN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2030 (USD MILLION)
TABLE 201. SPAIN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 202. SPAIN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. SPAIN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 204. SPAIN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. SPAIN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 206. SPAIN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 207. SPAIN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 208. UNITED ARAB EMIRATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 209. UNITED ARAB EMIRATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 210. UNITED ARAB EMIRATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 211. UNITED ARAB EMIRATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2030 (USD MILLION)
TABLE 212. UNITED ARAB EMIRATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 220. SAUDI ARABIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 221. SAUDI ARABIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 222. SAUDI ARABIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 223. SAUDI ARABIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2030 (USD MILLION)
TABLE 224. SAUDI ARABIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2030 (USD MILLION)
TABLE 225. SAUDI ARABIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 226. SAUDI ARABIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 228. SAUDI ARABIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 232. SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 233. SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 234. SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2030 (USD MILLION)
TABLE 236. SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 244. DENMARK POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 245. DENMARK POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 246. DENMARK POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 247. DENMARK POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2030 (USD MILLION)
TABLE 248. DENMARK POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2030 (USD MILLION)
TABLE 249. DENMARK POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 250. DENMARK POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 251. DENMARK POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 252. DENMARK POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. DENMARK POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. DENMARK POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 255. DENMARK POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 256. NETHERLANDS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 257. NETHERLANDS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 258. NETHERLANDS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. NETHERLANDS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 267. NETHERLANDS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 268. QATAR POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 269. QATAR POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 270. QATAR POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 271. QATAR POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2030 (USD MILLION)
TABLE 272. QATAR POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2030 (USD MILLION)
TABLE 273. QATAR POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 274. QATAR POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 275. QATAR POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 276. QATAR POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 277. QATAR POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. QATAR POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 279. QATAR POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 280. FINLAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 281. FINLAND POLYCYSTIC

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Polycystic Ovarian Syndrome Treatment market report include:
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Ferring International Center S.A.
  • Dr. Reddy’s Laboratories Limited
  • GlaxoSmithKline plc
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited

Table Information

Report AttributeDetails
No. of Pages188
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.68 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.09 Billion
Compound Annual Growth Rate6.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Polycystic Ovarian Syndrome Treatment Market Size, Share & Trends Analysis Report by Drug Class (Oral Contraceptives, Antiandrogens, Insulin-sensitizing Agent, Antidepressant, Anti-obesity), Surgery, Distribution Channel, and Region with Growth Forecasts, 2025-2030 - Product Image

Polycystic Ovarian Syndrome Treatment Market Size, Share & Trends Analysis Report by Drug Class (Oral Contraceptives, Antiandrogens, Insulin-sensitizing Agent, Antidepressant, Anti-obesity), Surgery, Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Polycystic Ovarian Syndrome Treatment Market Report 2025 - Product Image

Polycystic Ovarian Syndrome Treatment Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Polycystic Ovarian Syndrome - Pipeline Insight, 2025 - Product Image

Polycystic Ovarian Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Polycystic Ovarian Syndrome Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Polycystic Ovarian Syndrome Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 86 Pages
  • Global
From
Polycystic Ovary Syndrome (PCOS) Treatment - Global Strategic Business Report - Product Image

Polycystic Ovary Syndrome (PCOS) Treatment - Global Strategic Business Report

  • Report
  • 360 Pages
  • Global
From

About the Polycystic Ovary Syndrome Drug Market

Polycystic Ovary Syndrome (PCOS) is a hormonal disorder that affects women of reproductive age. It is characterized by irregular menstrual cycles, excess androgen production, and the formation of cysts on the ovaries. PCOS is a leading cause of infertility and can increase the risk of developing ovarian cancer. Drugs used to treat PCOS are typically hormone-based, such as oral contraceptives, anti-androgens, and gonadotropin-releasing hormone agonists. These drugs are used to regulate hormones, reduce androgen levels, and improve fertility. Additionally, lifestyle modifications such as diet and exercise are recommended to help manage PCOS symptoms. The PCOS drug market is highly competitive, with a range of products available from both generic and branded manufacturers. Companies such as Pfizer, Merck, and Novartis are some of the major players in the market. Other companies include Bayer, Sanofi, and Allergan. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.